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We demonstrate herein a method for quantifying glycosylation changes on glycoproteins. This
novel method uses MS data of characterized glycopeptides to analyze glycosylation profiles,
and several quality control tests were done to demonstrate that the method is reproducible,
robust, applicable to different types of glycoproteins, and tolerant of instrumental variability
during ionization of the analytes. This method is unique in that it is the first label-free
quantitative method specifically designed for glycopeptide analysis. It can be used to monitor
changes in glycosylation in a glycosylation site-specific manner on a single glycoprotein, or it
can be used to quantify glycosylation in a glycoprotein mixture. During mixture analysis, the
method can discriminate between changes in glycosylation of a given protein, and changes in
the glycoprotein’s concentration in the mixture. This method is useful for quantitative analyses
in biochemical studies of glycoproteins, where changes in glycosylation composition can be
linked to functional differences; it could also be implemented in the pharmaceutical industry,
where glycosylation profiles of glycoprotein-based therapeutics must be quantified. Finally,
quantification of glycopeptides is an important aspect of glycopeptide-based biomarker
discovery, and our quantitative approach could be a valuable asset to this field as well,
provided the compositions of the glycopeptides to be quantified are identifiable using other
methods. (J Am Soc Mass Spectrom 2009, 20, 1048–1059) © 2009 Published by Elsevier Inc. on
behalf of American Society for Mass SpectrometryGlycoproteomics, the study of the glycome at-tached to proteins, is a vital research fieldbecause as many as 50% of proteins in the
human body are glycosylated [1]. Glycoproteins are not
only common, but the glycans on the proteins are
significant because they are known to play important
biological roles in the body, including cell–cell interac-
tion, cell recognition, and protein regulation [2]. While
proteins are genetically encoded, the glycosylation on
proteins depends on the glycosylating enzymes that are
present and the local cell environment. Therefore, the
amount of enzymes and cofactors involved in glycosyl-
ation affect the extent of glycosylation on the glycopro-
tein [3]. Changes in glycosylation are known to occur
with the onset of certain diseases such as cancer [4–6].
Thus, detection methods to monitor changes in glyco-
sylation of glycoproteins are essential to determine
possible biomarkers for cancer and other diseases.
Methods to monitor changes in glycosylation of
proteins are not just important for biomarker studies.
These methods are also important for pharmaceutical
development, since glycoproteins have become increas-
ingly desirable targets as therapeutic agents. Some
example glycoprotein-based pharmaceuticals include
erythropoietin [7], follicle stimulating hormone [8], thy-
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such as the heavily glycosylated envelope glycoprotein
on the surface of the HIV virus [10–12]. Profiling and
quantifying the glycosylation on these products is im-
portant because studies indicate that glycosylation in
cell expression systems can differ from the glycosyla-
tion that occurs in the human body [10], and researchers
are currently striving to overcome this problem by
modifying the glycosylation, or humanizing it, during
protein production [13, 14]. Therefore, as methods are
developed for humanizing glycosylation, a quantitative
method that distinguishes between glycosylation profiles
on native and modified glycoproteins is imperative.
There are two options for quantifying glycosylation
on proteins: quantifying the glycans after enzymatic or
chemical cleavage from the protein or quantifying gly-
copeptides. While glycan analysis is clearly a more
established technique [15–18], this approach restricts
the amount of information one can obtain about the
glycosylation profile. For example, in purified, multiply
glycosylated proteins, the study of released glycans
would only provide aggregate information about the
glycosylation on a protein, and it would not provide
information about the glycosylation profile at a specific
glycosylation site. Yet it is well established that moni-
toring glycosylation profiles at individual glycosylation
sites is important because the glycosylation at particular
sites in a protein can modulate the protein’s structure,
function, or metabolic clearance [19]. Since many ther-
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the examples mentioned above, the analysis of released
glycans is problematic in that it does not provide
glycosylation site-specific information about the glyco-
sylation profiles of the protein.
In biomarker analysis, quantifying the released gly-
cans has an additional disadvantage in that all the
information about the proteins from which the glycans
originated is lost. This introduces many problems in
biomarker discovery, such as not being able to identify
whether or not the glycan’s concentration increased
because a protein containing that glycan was overex-
pressed, or if one or several proteins’ glycosylation
profile changed, causing the glycan to be more abun-
dant, even though the protein level(s) are not altered
[4]. In contrast to glycan analysis, glycopeptide analysis
provides glycosylation site-specific information for pu-
rified proteins [17, 20, 21], and it could potentially be
useful in distinguishing between glycosylation changes
and protein expression changes, since the protein infor-
mation is encoded in the glycopeptide. For the reasons
described herein, we are pursuing quantitative methods
for glycopeptides.
There are two strategies to quantify changes in the
glycosylation of proteins, either differentially labeling
sets of samples or using label-free approaches. Several
labeling techniques exist, including those with detec-
tion by optical methods [22, 23] and mass spectrometry
[24–26]. One common quantitation strategy using label-
ing and optical detection involves the use of lectins to
bind glycoproteins in complex samples, then detecting
different types of glycosylation due to differential bind-
ing of the lectins. Because different lectins have differ-
ent specificities for classes of N-linked glycans, it is
possible to use lectins to distinguish between high
mannose and complex type glycosylation, for example.
Detecting the binding of lectins to glycans, glycopep-
tides, or glycoproteins is done by either tagging the
lectins [22, 27] or tagging the analyte [23] with a
fluorophore, followed by the monitoring of a change in
fluorescence upon binding. If the ultimate quantitative
goal is to detect changes in classes of N-linked glycans,
optical methods that detect differences in lectin binding
are ideal and have very low detection limits. However, the
use of lectin microarrays is incapable of observing subtle
glycosylation changes, such as a change in the number of
mannoses present on a high mannose glycan [23].
If detecting subtle changes in glycosylation is re-
quired, such as distinguishing between the addition or
subtraction of one monosaccharide unit between glyco-
protein samples, other detection strategies, for example
mass spectrometry, must be employed. Quantitative
MS analysis of glycosylated species using isotopic la-
bels is a growing field. Currently, methods are available
to analyze glycans directly [25, 26, 28–31], and the
strategy used in some of these approaches could poten-
tially be applied to glycopeptide analysis. The biggest
draw-back is that many of these labeling methods are
also limited to two sample sets, a control group and atest group; therefore, if more samples need to be com-
pared to one another, such as analyzing the glycosyla-
tion differences between five different vaccine candi-
dates, binary labeling approaches become difficult to
implement.
An alternative strategy for accomplishing a quanti-
tative analysis is to use label-free approaches. These
methods have the potential to compare multiple sam-
ples with ease. Changes in intensities of mass spectral
peaks have been assessed by comparing different sam-
ple sets through either glycan analysis [4] or glycopep-
tide analysis [32]. Because signal intensities can vary
between mass spectrometric samples, label-free ap-
proaches are not as commonly used for quantitative
analysis [26, 33].
To alleviate much of the variation due to changes in
MS response among samples, normalization of data has
been applied in proteomics studies [33–36]. Many pro-
teomics researchers employ a normalization technique
that involves dividing intensities of individual peaks by
the total intensity from all peaks in the spectrum
[33–35]; this approach is fundamentally similar to the
approach by Wang et al., where spectra are normalized
by calculating an intensity ratio for one spectrum versus
another by doing pair-wise comparisons of peak inten-
sities, for all the peaks in the spectra [36]. In the work
presented here, this concept of normalization is built-
upon to produce a label-free quantitative method for
glycopeptide analysis. While in the proteomic field one
can obtain reliably quantitative data by normalizing the
data to the total ion abundance [33–35], this method is
potentially problematic for glycopeptide analysis be-
cause the glycopeptides ionize weakly, compared with
the nonglycosylated peptides that may also be present.
Therefore, small changes in the presence of nonglyco-
sylated interferents could impart large variability in a
quantitative assay when the total ion current (or pair-
wise comparison of all the peaks) is used to normalize
the ion abundances of the analytes. To remedy this
problem, a new normalization method is described
herein, where the ion abundance from each glycopep-
tide is divided by the total intensity of all glycopeptide
peaks present in a given spectrum (excluding all ions
that are not assigned as glycopeptides). As demon-
strated herein, this normalization produces reproduc-
ibly quantitative, label-free data.
The second major innovation of this work is using a
two-tiered quantitative analysis. In the first tier of the
analysis, the abundances of glycopeptide ions within a
given sample are compared to each other. This internal
analysis is used to generate a glycosylation profile for
the sample, where the abundance of each glycoform is
rank-ordered (from smallest to largest) within the sam-
ple. The second tier of the analysis involves comparing
this generated glycopeptide profile from one sample to
the profile of another sample. By comparing whole
profiles, and not just the abundance of a given glyco-
form, one can readily discriminate between changes in
the overall glycosylation profile of a protein and changes
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mixture of other species. The described method, which
presents a new normalization method custom-designed
for the challenges of glycopeptide analysis, and a new
approach to glycosylation profiling, where internal and
external analyses are completed in parallel, is useful for
those interested in glycosylation profiling of biophar-
maceuticals as well as those quantifying mixtures of
glycoproteins for various applications, including bi-
omarker analysis.
Experimental
Materials and Reagents
All reagents were obtained in high purity from Sigma
Aldrich except when noted otherwise. Ribonuclease B
(RNase B) 80% pure, asialofetuin, urea, -mannosidase
from Canavalia ensiformis, dithiothreitol (DTT), iodoacet-
amide (IAA), acetic acid, Sepharose CL-4B, HPLC grade
1-butanol, and HPLC grade ethanol were all purchased
from Sigma Aldrich (St. Louis. MO). Sequencing grade
modified trypsin was purchased from Promega (Madison,
WI). Ammonium bicarbonate (NH4HCO3) was purchased
from Fluka (Milwaukee, WI). HPLC grade methanol was
purchased from ThermoFisher Scientific (Fairlawn, NJ).
Water was purified by a Millipore Direct Q-3 water
purification system (Billerica, MA).
Enzymatic Glycan Trimming with -Mannosidase
To analyze glycosylation change, one RNase B sample was
subjected to cleavage by the enzyme -mannosidase as
described by Toumi and Go [37]. Briefly,300 g of RNase
B was dissolved in enough 10 mM NH4HCO3 (pH 5.0) to
make a 2 mg/mL solution. The enzyme, -mannosidase,
was added in an enzyme:protein ratio of 1:1000 (mol/
mol). The sample was allowed to incubate for 24 h at
37 °C. Enough NaOH was added to raise the pH of the
sample to approximately pH 8.0. The sample was then
digested with trypsin, and subjected to glycopeptide en-
richment, mass spectrometry, and data analysis, as de-
scribed below.
Glycoprotein Protease Digestion
Approximately 300 g of glycoprotein was dissolved in
25 mM NH4HCO3 (pH 7.5–8.0) containing 4 M urea, to
a glycoprotein concentration of 1 mg/mL (asialofetuin),
or 2 mg/mL (RNase B). To this solution, dithiothreitol
(DTT) was added to a final concentration of 15 mM, and
it was incubated at room temperature for 1 h. Following
the incubation, iodoacetamide (IAA) was added to a
final concentration of 25 mM, and the reaction was
stored at room temperature, in the dark, for 1 h.
Additional DTT was added to a final concentration of
40 mM to neutralize excess IAA. The solution was
diluted with 25 mM NH4HCO3 until the urea concen-
tration was less than 1 M. Trypsin was added at a 1:50(wt/wt) protease/glycoprotein ratio. The solution was
allowed to incubate at 37 °C for 18 h and stopped by the
addition of 1 L acetic acid per 100 L solution.
Glycopeptide Enrichment
To remove the nonglycosylated peptides from sam-
ples, a method adapted from Wada et al. [38, 39] was
used as also described by Zhang et al. [40]. Briefly,
the digest solution was added to 800 L of 5:1:1
(vol/vol) 1-butanol/ethanol/water and 25 L Sepha-
roseCL-4B, and shaken gently for 45 min before centrif-
ugation and extraction of the solution layer. Samples
were washed twice with the addition of 1 mL 5:1:1
(vol/vol) 1-butanol/ethanol/water with gentle shaking
for 5 min followed by the same centrifugation and
extraction. After washing, 1 mL of 1:1 (vol/vol) etha-
nol/water was added, and samples were allowed to
stand for 30 min, followed by gentle shaking for 30 min.
The samples were centrifuged, and the solution layer was
extracted and collected. The ethanol/water extraction step
was repeated a second time. The combined samples were
dried using a Labconco centrivap cold trap (Kansas City,
MO) and stored at 20 °C until use.
For the quality control studies, the samples were
reconstituted before MS analysis in 1:1 (vol/vol) water/
methanol containing 0.5% acetic acid, to a final glyco-
peptide concentration of 10 M. After the initial MS
analysis, the remaining RNase B was stored in the
reconstituted solvent at 20 °C for 8 wk for a second
MS analysis testing the method’s robustness.
For the mixture analysis experiments, RNase B and
asialofetuin glycopeptide digest samples were each
reconstituted in 100 L 1:1 (vol/vol) water/methanol
containing 0.5% acetic acid. The reconstituted samples
of asialofetuin and RNase B glycopeptides were com-
bined into four separate vials in varying concentrations.
A total of four samples were prepared where the
asialofetuin glycopeptides retained a fixed concentra-
tion of 1 M, and the RNase B glycopeptide concentra-
tion prepared at 1 M, 3 M, 5 M, and 10 M,
respectively, in each mixture vial (see Table 1).
Mass Spectrometry
MS and MS/MS data were acquired on a Thermo
electrospray ionization-linear ion trap-Fourier trans-
form ion cyclotron resonance (ESI-LIT-FTICR) mass
spectrometer, (San Jose, CA), containing a 7 Tesla
actively shielded magnet. The samples were injected by
direct infusion at a flow rate of 1 L/min in positive ion
mode. The spray voltage was optimized to maximize
Table 1. Glycoprotein mixture concentrations
Sample no. 1 2 3 4
RNase B 1 M 3 M 5 M 10 M
Asialofetuin 1 M 1 M 1 M 1 M
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The nebulizing gas, N2, was set to 10 psi, and the
capillary temperature was 200 °C. MS data were ac-
quired with 100,000 resolutions for m/z 400, over a mass
range of m/z 500–2000 for RNase B and a mass range of
m/z 800–2000 for asialofetuin. For all MS1 data, 50 scans
(with each containing 10 microscans) were averaged.
For MS/MS data, the precursor ion was isolated with a
2 Da isolation range; the activation time was set to 30
ms, the activation qz was 0.250, and the activation
energy was 30%, as defined by the instrument software.
There were 20 to 30 scans (each containing 10 mi-
croscans) averaged during acquisition of MS/MS data.
The instrument software used was Xcalibur version 1.4
SR1 (ThermoFisher Scientific, San Jose, CA).
Data Analysis
The glycopeptide ions were assigned by matching the-
oretical masses to the actual masses acquired in the MS
data. Prediction tables of possible theoretical glycopep-
tide masses were constructed for each glycoprotein
studied. The prediction table was generated by the
following steps: the amino acid sequence of each pro-
tein was obtained from Uniprot (http://beta.uniprot.
org), and a theoretical tryptic digest of the given
glycoprotein was completed by importing that se-
quence into Protein Prospector (http://prospector.ucsf.
edu/), which calculates the possible tryptic fragments.
The mass of the resulting tryptic fragments were ad-
justed to account for the alkylation of cysteine residues
by iodoacetamide. The peptide masses that contained
glycosylation sites were added to possible N-linked
glycan masses to give predicted glycopeptide masses.
The glycan masses used in this case were the known
glycans that are appended to these proteins, as de-
scribed in references [41, 42], for asialofetuin and RNase
B, respectively. After combining the peptide masses
with the known glycan masses, the calculated glyco-
peptide masses were converted to m/z (for the 1, 2,
3, 4, and 5 charge states) for comparison with the
MS1 data. A maximum of two missed tryptic cleavages
was considered, as well as the presence of protonated
and sodiated glycopeptide peaks. Possible peak identi-
ties from the MS data were confirmed through analysis
of MS/MS data taken on each peak in the spectrum, as
described previously [43].
Data Treatment for Quantitative Method
After identifying all the glycopeptide peaks in the
spectrum, six steps were taken to process the data for
quantitative analysis. The steps were (1) peak lists of
m/z and intensity were generated in Xcalibur, and
transferred to Microsoft Excel; (2) the first four isotopic
peaks of each glycopeptide ion were summed to obtain
each glycopeptide’s peak intensity; (3) glycopeptide
peak intensities from all glycopeptide peaks in a spec-
trum were summed to calculate the total glycopeptideintensity. (4) The glycopeptide peak percentage was
computed by eq 1, below. This percentage reports how
large each glycopeptide peak is, relative to the total
glycopeptide intensity.
Glycopeptide Peak %

Glycopeptide Peak Intensity
Total Glycopeptide Intensity
 100
(5) Glycopeptide peak percentages corresponding to the
same glycopeptide composition, but containing differ-
ent charge states and/or charge carriers, were summed
to give the glycopeptide percentage. If glycopeptides
from a given glycosylation site also were generated
with differing levels of missed tryptic cleavages, these
species were also combined into one glycopeptide per-
centage. This percentage is a measure of how abundant
a given glycopeptide composition is in the sample,
regardless of whether or not it ionizes as a single peak,
or as several peaks corresponding to different charge
states, different numbers of sodiated adducts, or differ-
ent lengths of peptide, due to missed tryptic cleavage;
(6) glycopeptide percentages were rank ordered to
determine which glycopeptides were most abundant in
the spectrum, and the rank order among different
samples was compared.
Results and Discussion
Developing a Quantitative Method for
Glycopeptides
Since the goal is to develop a label-free quantitative
approach for glycopeptides, the first problem that must
be overcome is the fact that ion abundances in mass
spectra are not very reproducible in run-to-run analy-
ses. Figure 1 demonstrates this by showing MS data of
glycopeptides generated from two replicate samples of
asialofetuin digested with trypsin. The brown and red
stars in Figure 1 label peaks that correspond to two
different charge states of a single glycopeptide compo-
sition, the 4 and 5 charge states, respectively. The
intensity of the peaks labeled with the brown stars does
not change between Figure 1a and b because this is the
base peak in both spectra. The peaks labeled with red
stars, on the other hand, have a much higher intensity in
Figure 1a compared with Figure 1b, demonstrating that
the ions partitioned differently into different charge
states in the two analyses. The insets in Figure 1a and b
show the intensities of sodiated adducts are also different
when the two spectra are compared. The peaks labeled
with green stars, which correspond to sodiated adducts of
some of the glycopeptides, have much lower intensities in
Figure 1b compared with Figure 1a. Consequently, the
distribution between charge states and sodiated adducts
of the glycopeptide peaks in Figure 1a is different than the
distribution of the glycopeptide peaks in Figure 1b. There-
fore, it makes sense that the peaks from Figure 1a and b
en st
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relative abundance alone.
To alleviate the problem that changes in the form in
Figure 1. (a) and (b) Mass spectra from two dif
brown stars show the same glycopeptide in diffe
states vary from sample to sample. Insets: a zo
sodiated adducts of the glycopeptides. The gre
whose intensity changes in spectrum a and b.which the peaks ionize leads to irreproducible peakintensity data, the relative abundances of the peaks
containing the same glycopeptide composition but dif-
fering in the charge state and charge carrier were
t glycopeptide samples of asialofetuin. Red and
harge states; the intensities of each of the charge
-in region of the spectrum containing multiple
ars indicate sodiated adducts of glycopeptidesferen
rent c
omedcombined. By combining these values, the problem that
1053J Am Soc Mass Spectrom 2009, 20, 1048–1059 LABEL-FREE QUANTITATION: A NEW GLYCOPROTEOMICS APPROACHthe peaks partition differently into different charge
states is mitigated. Once all the charge states and charge
carriers for a particular glycopeptide composition are
combined, we report the results as a percent of the total
glycopeptide ion signal, and this value is henceforth
referred to as the glycopeptide percentage. [Reporting
the values as percentages of all the glycopeptides
present in the spectrum is a normalization method used
to mitigate the run-to-run ionization discrepancies that
are problematic in label-free quantitative approaches, as
described in the introduction.] After obtaining the gly-
copeptide percentages for each of the different glyco-
Table 2. Glycopeptide peaks identified in asialofetuin FT-MS da
Theoretical m/z Observed m/z
Mass
error1
Charge
state
# of
Na
1059.6757 1059.6767 0.9 5 0
1064.0722 1064.0783 5.7 5 1
1068.4687 1068.4746 5.5 5 2
1121.8122 1121.8183 5.4 3 0
1129.1397 1129.1438 3.6 3 1
1132.7022 1132.7059 3.3 5 0
1137.0987 1137.1055 6.0 5 1
1141.4952 1141.5009 5.0 5 2
1145.8917 1145.8944 2.4 5 3
1150.2882 1150.2762 10.4 5 4
1160.5443 1160.5529 7.4 4 0
1164.5106 1164.5156 4.3 3 0
1166.0400 1166.0479 6.8 4 1
1171.5356 1171.5389 2.8 4 2
1171.8381 1171.8426 3.8 3 1
1243.5230 1243.5300 5.6 3 0
1250.8505 1250.8559 4.3 3 1
1251.8274 1251.8252 1.8 4 0
1257.3230 1257.3286 4.5 4 1
1258.1780 1258.1814 2.7 3 2
1262.8186 1262.8220 2.7 4 2
1265.5055 1265.5081 2.1 3 3
1268.3143 1268.3221 6.1 4 3
1273.8099 1273.8070 2.3 4 4
1286.2213 1286.2286 5.7 3 0
1293.5488 1293.5582 7.3 3 1
1300.8763 1300.8730 2.5 3 2
1308.2038 1308.2108 5.4 3 3
1324.3428 1324.3526 7.4 4 0
1329.8385 1329.8471 6.5 4 1
1335.3341 1335.3426 6.4 4 2
1415.6259 1415.6355 6.8 4 0
1421.1215 1421.1297 5.8 4 1
1426.6171 1426.6263 6.4 4 2
1432.1128 1432.1185 4.0 4 3
1437.6084 1437.6084 0.0 4 4
1547.0587 1547.0695 7.0 3 0
1554.3842 1554.3688 9.9 3 1
1668.7674 1668.7771 5.8 3 0
1676.0949 1676.1073 7.4 3 1
1682.2147 1682.2204 3.4 2 0
1683.4224 1683.4358 8.0 3 2
1765.4547 1765.4575 1.6 3 0
1864.7808 1864.7876 3.6 2 0
1Mass error is reported in ppm.color correspond to biantennary and triantennary glycans, respectively. Ion
together to generate the “glycopeptide percentage” for each species.peptide compositions, the compositions are ordered
based on their percentage from smallest to largest (rank
ordered), so an internal comparison of the glycan pro-
file can be made. A list of all the identified glycopeptide
ions from asialofetuin are shown in Table 2, and the
chart is color-coded to show which species’ ion abun-
dances were combined. For example, all the blue entries
correspond to glycopeptides with the peptide sequence
RPTGEVYDIEIDTLETTCHVLDPTPLANCSVR. The
darker blue indicates the biantennary glycans contain-
ing that amino acid sequence, and the lighter blue
indicates the triantennary glycans. The intensities of
Peptide Carbohydrate
TGEVYDIEIDTLETTCHVLDPTPLANCSVR [Hex]5[HexNAc]4
““
““
“RSDNLPALLPCD
““
TGEVYDIEIDTLETTCHVLDPTPLANCSVR [Hex]6[HexNAc]5
““
““
““
““
HAVEVALATFNAESNGSYLQLVEISR [Hex]5[HexNAc]4
“RSDNLPALLPCDP
HAVEVALATFNAESNGSYLQLVEISR “
““
“RSDNLPALLPCDP
5]cANxeH[6]xeH[RSDNLPALLPCD
““
HAVEVALATFNAESNGSYLQLVEISR “
““
“RSDNLPALLPCD
HAVEVALATFNAESNGSYLQLVEISR “
“RSDNLPALLPCD
HAVEVALATFNAESNGSYLQLVEISR “
““
“RSDNLPALLPCDP
““
““
““
TGEVYDIEIDTLETTCHVLDPTPLANCSVR [Hex]5[HexNAc]4
““
““
5]cANxeH[6]xeH[“
““
““
““
““
HAVEVALATFNAESNGSYLQLVEISR [Hex]5[HexNAc]4
““
5]cANxeH[6]xeH[“
““
4]cANxeH[5]xeH[RSDNLPALLPCD
HAVEVALATFNAESNGSYLQLVEISR [Hex]6[HexNAc]5
TGEVYDIEIDTLETTCHVLDPTPLANCSVR [Hex]5[HexNAc]4
5]cANxeH[6]xeH[RSDNLPALLPCDta
RP
PCL
RP
VV
CLK
VV
CLK
PCL
VV
PCL
VV
PCL
VV
CLK
RP
VV
PCL
VV
RP
PCL
The color of the rows (blue, red, or green) represent the three glycosylation sites of asialofetuin, whereas the darker and lighter shades of a given
abundances corresponding to the same color and shade are added
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single glycopeptide percentage.
Figure 2 illustrates the benefit of combining the differ-
ent charge states and charge carriers for the asialofetuin
glycopeptide data. Figure 2a shows a portion of the rank
order of ion abundances between the two asialofetuin
samples from Figure 1 when the ion abundances are not
combined, before ranking the glycopeptides from smallest
to largest. The rank order is clearly very different between
the two samples. However, once the different charge
states and charge carriers for each of the glycopeptide
compositions are combined, the rank order is highly
reproducible between the two samples (Figure 2b).
Quality Control Experiment 1—Robustness
Since the goal was to develop a robust quantitation
method that can detect changes in glycopeptides’ inten-
sities for different samples, one important feature is that
the method must produce the same results for the same
Figure 2. (a) Rank order of glycopeptide ions from the data in
Figure one. (b) Rank order of glycopeptide compositions, after
combining all charge states and sodium adducts of ions with the
same composition, before rank-ordering the components. Repro-
ducible glycosylation profiles are achieved only in (b), when
charge states and sodium adducts of the same species are
combined.glycoprotein batch. For example, small differences that
could be introduced during digestion or glycopeptide
enrichment and dilution for MS analysis, should not
cause changes in the quantitation results. Otherwise,
the method would not be robust. To test robustness, a
quality control experiment was developed where four
replicate samples of asialofetuin were each digested
and prepared separately. After each sample was sub-
jected to MS analysis, the glycopeptide percentages
were calculated as described above, and were subse-
quently rank ordered, by percentage, from smallest to
largest. The results of this experiment are displayed in
Figure 3a. It is evident from the figure that the same
rank order was observed for all four samples. However,
the percentages between each sample tended to vary
slightly, albeit not enough to change the rank order.
This variability in percentage of asialofetuin glycopep-
tides is attributed to change in the distribution of
sodiated adducts between samples. Different numbers
of sodiated adducts can have slightly different ioniza-
tion efficiencies. Therefore, when samples produce
spectra with different intensities of sodiated adducts,
combining the percentages of the different sodiated
adducts can introduce a small variability in the percent-
ages of each glycopeptide composition. This is not a
significant problem, however, because the changes are
small enough so that the rank order did not vary
between the samples.
Quality Control Experiment 2—Applicability to
Different Glycoproteins
Once the method was confirmed to produce reproduc-
ible results for asialofetuin, a second glycoprotein with
very different properties than asialofetuin was analyzed
to ensure the method is applicable for a wide variety of
glycoproteins. RNase B was chosen for the analysis
because it is much smaller than asialofetuin; it has only
one glycosylation site; and it has a different type of
glycosylation, high mannose type glycans, see Table 3.
RNase B was subjected to the same sample preparation
conditions as asialofetuin. Four replicate samples of
RNase B were digested and analyzed. Unlike the asia-
lofetuin data, RNase B glycopeptides did not ionize as
sodiated adducts. The RNase B glycopeptides did ion-
ize in multiple charge states, and the spectra also
contained peaks corresponding to missed tryptic cleav-
ages of the glycopeptides (data not shown). The missed
cleavages are likely the result of the glycosylation
blocking the cleavage site, as described earlier [44],
since several arginine and lysine residues are located
very near the glycosylation site. See the amino acid
sequence in Table 3. These missed tryptic cleavages
could potentially interfere with reproducible quantita-
tive analysis, if the digestions do not generate identical
proportions of peptides with missed tryptic cleavages
near the glycosylation sites. To mitigate the potential for
quantitative error due to differences in the digestion,
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ation site and a given glycan composition were com-
bined with species that contained the same glycan
composition and glycosylation site, but different levels
of missed tryptic cleavages. The results from the RNase
Figure 3. Similarity of the glycopeptide profiles for asialofetuin
(a) and RNase B (b). The percentage of each glycopeptide composi-
tion is plotted for four replicate samples. The glycopeptide compo-
sitions are shown on the x-axis in order of their abundance in the
spectrum. In each case, the rank order (smallest percentage to
largest percentage) does not change; small fluctuations are ob-
served in the actual percentage of each glycopeptide composition
among the four replicate samples.
Table 3. Comparison of glycoproteins
RNase B
MALKSLVLLSLLVLVLLLVRVQPSLGKETAAAKFERQHMDSSTS
AASSSNYCNQMMKSRNLTKDRCKPVNTFVHESLADVQAVC
SQKNVACKNGQTNCYQSYSTMSITDCRETGSSKYPNCAYKT
TQANKHIIVACEGNPYVPVHFDASV
aDk5.61
etisnoitalysocylgdeknil-N1
snacylgesonnamhgiHB experiments are illustrated in Figure 3b. The RNase B
glycopeptide data also exhibits a consistent rank order
among the replicate samples.
Quality Control Experiment 3—Instrument
Precision
The use of a mass spectrometer over extended time
frames can lead to reproducibility problems in label-
free quantitative assays. Therefore, to ensure that minor
changes in the instrument conditions do not lead to
inaccuracies in assigning the rank order of glycopep-
tides, the four samples of glycopeptides from RNase B
were run on two different dates, eight weeks apart.
Between analyses, the samples were stored at 20 °C.
Under these conditions, the RNase B glycopeptides do
not degrade; therefore any changes in the rank order of
the glycopeptide compositions would be attributed to
instrument variability over time [Dalpathado, D. S.;
Irungu, J.; Zhang, Y.; Go, E. P.; Desaire, H., unpublished
data]. Before using our quantitative method on the two
sets of data, we first determined whether or not the
mass spectra showed deviations in peak intensities
between weeks zero and eight, by comparing the raw
ion abundances for each of the glycopeptides. Table 4
shows the results for the relative abundances of several
peaks that were acquired from one RNase B glycopep-
tide sample, before and after the 8-wk storage condi-
tions. The relative abundance increases in the 3 charge
state in week 8 compared to week 0, while the relative
abundance in the 2 charge state decreases in week 8,
compared to week 0. This is another example that
shows the ions can partition themselves differently into
different charge states. In this case, drastically different
ion abundances were acquired for the exact same sam-
ple. Fortunately, the quantitative method described
herein is designed to accommodate this variability by
combining glycopeptide peak percentages for the same
glycopeptide, partitioned into different charge states.
After combining the glycopeptide peak percentages as
described above, the rank order of RNase B glycopep-
tides was obtained, and the data is shown in Figure 4
for the two different time points. The glycopeptide
percentages for RNase B glycopeptides illustrated in
Asialofetuin
FVLLFCLAQLWGCHSIPLDPVAGYKEPACDDPDTEQAALAAVD
KHLPRGYKHTLNQIDSVKVWPRRPTGEVYDIEIDTLETTCHVLD
PLANCSVRQQTQHAVEGDCDIHVLKQDGQFSVLFTKCDSS
SAEDVRKLCPDCPLLAPLNDSRVVHAVEVALATFNAESNGSYL
VEISRAQFVPLPVSVSVEFAVAATDCIAKEVVDPTKCNLLAEKQ
FCKGSVIQKALGGEDVRVTCTLFQTQPVIPQPQPDGAEAEAPS
PDAAGPTPSAAGPPVASVVVGPSVVAVPLPLHRAHYDLRH
SGVASVESSSGEAFHVGKTPIVGQPSIPGGPVRLCPGRIRYFKI
aDk
setisnoitalysocylgdekni
snacylgxelpMKS
YIN
PT
PD
QL
YG
AV
TF
5.83
l-N3
moC
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deviations, and the rank order is retained between the
two runs.
The above experiments demonstrate that for a puri-
fied sample, the quantitative method described pro-
duces reproducible data, even under different instru-
mental conditions, and the reproducibility is unaltered
after repeating the protease digestion and sample prep-
aration conditions. Also, the method successfully ana-
lyzed two different glycoproteins that had a variety of
different features, including varying numbers of glyco-
sylation sites and different types of glycosylation. In
summary, these studies demonstrate that the quantita-
tive method described would be useful for classifying
glycosylation changes in purified proteins, which is
useful in a variety of biopharmaceutical applications, as
described in the introduction.
Table 4. Differences in relative abundance for glycopeptide ion
Charge state Composition m/z
3 [Hex]5[HexNAc]2  SRNLTKDR 735.995
3 [Hex]6[HexNAc]2  SRNLTKDR 790.013
3 [Hex]7[HexNAc]2  SRNLTKDR 844.031
3 [Hex]8[HexNAc]2  SRNLTKDR 898.048
3 [Hex]9[HexNAc]2  SRNLTKDR 952.066
2 [Hex]5[HexNAc]2  SRNLTKDR 1103.489
2 [Hex]6[HexNAc]2  SRNLTKDR 1184.516
2 [Hex]7[HexNAc]2  SRNLTKDR 1265.542
2 [Hex]8[HexNAc]2  SRNLTKDR 1346.569
2 [Hex]9[HexNAc]2  SRNLTKDR 1427.595
* Two data sets using the same sample, analyzed 8 weeks apart.
Figure 4. Graphical depiction of the quantified amounts of
RNase B glycopeptides at two different time points. The mean
from four digest samples was plotted. Error bars indicate the
standard deviation. The glycopeptides are plotted from left to
right in order of increasing abundance. The rank order does not
change, even when the sample is re-analyzed 8 weeks after the
original analysis date.Mixture Analysis
In addition to characterizing the glycosylation on biop-
harmaceuticals, it would be ideal if this method of
quantifying glycosylation profiles could also be used in
other types of applications, for example in studies
where a mixture of proteins is present. When a mixture
of glycopeptides is analyzed, one current roadblock is
being able to determine why the particular glycopep-
tide ion has changed in abundance, i.e., is it due to
changes in glycosylation on a given protein or due to
changes in the protein’s concentration, relative to the
other species being analyzed [4]? Our method, which
characterizes the entire glycosylation profile for a given
glycoprotein as part of the quantitation process, is
ideally suited to solving this problem.
To demonstrate that the quantitative method de-
scribed herein can also distinguish between glycosyla-
tion changes and net protein abundance changes when
proteins are present in a mixture, glycopeptides from
the two proteins described above were combined in
several different ratios, and the resulting samples were
analyzed. In each case, glycopeptides from asialofetuin
were present at a concentration of 1 M, while the
glycopeptides from RNase B were present at varying
concentrations, between 1 and 10 M (see Table 1). MS
data of the mixed samples was acquired, and the rank
order for each of the glycopeptides present was ob-
tained, as described previously. The quantitative results
are shown in Figure 5a. This figure shows data for the
RNase B glycopeptides for the four samples. Regardless
of the relative concentrations of the two proteins, the
rank order of the glycans for the given glycoprotein,
RNase B, did not change. In every case, the Man9
glycopeptides from RNase B were present in lowest
abundance and the Man5 glycopeptides were present in
highest abundance, among the RNase B glycoforms.
This demonstrates that varying the concentration of
protein does not impact the rank order of the glycopep-
tides for a given glycoprotein. In addition, the order
observed in Figure 5a is the same order as observed for
RNase B alone, (in Figure 3b and 4), demonstrating that
RNase B*
Relative abundance week 0 Relative abundance week 8
32.7 77.6
34.2 66.8
14.8 31.1
36.1 50.8
16.1 21.0
67.4 40.0
30.1 15.7
6.4 3.3
5.7 3.8
0.8 0.6s from
8
4
0
6
2
9
3
7
1
5the presence of other proteins does not interfere with
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glycopeptides. Most importantly, when one compares
the data for a given glycopeptide, for example, Man5,
the data in Figure 5a clearly demonstrate that the
glycopeptide percentages increase as the concentration
of the protein increases. Therefore, the data described
herein can clearly distinguish between changes in a
glycosylation profile and changes in a protein’s concen-
tration. For the four samples in Figure 5a, the glycosyl-
ation profile was identical; yet the concentrations of a
given glycopeptide increased as the protein concentra-
tion increased.
It is important to note a rare case where this method
Figure 5. (a) Glycopeptide profiles for RNase B in mixtures of
RNase B and asialofetuin. Glycopeptide percentages of all the RNase
B glycoforms are increased as the concentration of RNase B is
increased in the mixture; rank order of the glycoforms is conserved.
(b) RNase B before and after cleavage with -mannosidase. Man8
andMan9 decreased in glycopeptide percentage, while Man1, Man2,
Man3, and Man4 increased in glycopeptide percentage upon treat-
ment with the enzyme. (Note: The glycans are plotted on the X axis
in (b) based on the number of mannose residues in the glycan, not
based on increasing rank order. However, it is still visually evident
from the graph that the two samples in (b), did not have a consistent
rank order for their glycans.)would detect a false positive for protein concentrationchange: If a protein’s glycosylation sites were only
partially occupied in one sample, but fully occupied in
another sample, the described method would incor-
rectly indicate that the protein with the fully occupied
glycosylation sites had an increase in its concentra-
tion. In assessing protein concentration, this method
does not account for the possibility of partially occu-
pied glycosylation sites. If one needs to distinguish
between protein concentration change and a change
in glycosylation site occupancy, these two cases could
easily be distinguished by determining the glycosyl-
ation site occupancy of the proteins in a separate
experiment.
Monitoring Changes in Glycosylation
To demonstrate that the method can effectively detect
changes in glycan population, the glycans on RNase B
were modified by cleaving mannose residues with the
enzyme, -mannosidase from Canavalia ensiformis. Two
experiments were performed simultaneously; one where
RNase B was allowed to be digested with -mannosidase
and a second experiment with RNase B unmodified. Both
samples were subjected to the same sample preparation
and data analysis conditions. Under these conditions, the
modified glycoprotein should have fewer mannoses
present, since the enzyme cleaves mannose residues. Fig-
ure 5b illustrates the results from this experiment. The
figure shows that the protein with modified glycosylation
had reduced glycopeptide percentages for Man8 and
Man9, and the glycopeptide percentages for Man1, Man2,
Man3, and Man4 increased, as expected. This clearly
shows that the quantitative method is capable of detecting
changes in glycosylation.
This quantitative method is similar to any other
analytical method in that it has limitations. First of all,
this method is only applicable to quantifying glycopep-
tides that have been previously characterized. It is
expected that other methods would be used to identify
all the glycopeptides present, before using the quanti-
tative method. Appropriate complementary techniques
for identifying glycopeptide compositions are well-
described in the literature [12, 17, 20, 21, 40, 43, 45, 46].
The second major limitation of this method is that it is
only applicable to glycoproteins containing neutral gly-
coforms; a mixture of sialylated glycoforms, or other
negatively charged species, and neutral glycans typi-
cally requires the use of both positive and negative
mode to accurately identify the glycoforms present [40].
This method does not currently allow for calculating
glycosylation profiles from a combination of positive
mode and negative mode data. Finally, as described
above, the method cannot distinguish between changes
in glycosylation site occupancy and glycoprotein con-
centration changes. Even though this method has some
limitations, its utility for quantifying glycosylation pro-
files has many uses in glycoprotein analysis.
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This article describes a new label-free quantitative
method that can be applied to purified proteins as well
as glycoprotein mixtures. The method is able to distin-
guish between glycoprotein concentration changes and
changes in glycosylation. The method was validated
with several control experiments. The first control ex-
periment analyzed replicate samples of glycopeptides
from one glycoprotein, asialofetuin. The results from
this experiment illustrate that the rank order of glyco-
peptides is consistent in all replicate samples, with
slight variation in glycopeptide percentages. To be
confident that the method would be applicable to a
large set of glycoproteins, a second glycoprotein, RNase
B, with very different properties, was analyzed. RNase
B results are also very consistent among four replicate
samples, and the rank order of the glycoforms is re-
tained among the replicate samples. Because the repli-
cate samples in the two glycoproteins studied were
digested in different vials before analysis, the results
demonstrated that minor changes in digestion condi-
tions did not alter the rank order. The third quality
control experiment measured the ability of the method
to tolerate small changes in the instrument conditions.
The same RNase B glycopeptide samples were run on
two different dates, 8 wk apart, and subsequently
analyzed with the quantitative method. Similar RNase
B glycopeptide percentages were observed, with no
change in rank order; therefore similar samples can
confidently be analyzed by this method at different
times. This new quantitative method would be useful
for anyone studying glycosylation profiles of proteins,
either as purified proteins (as in the case of pharmaceu-
tical development) or as glycoprotein mixtures, such as
in the search for glycan-based biomarkers.
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